Neurol. praxi. 2021;22(4):278-282 | DOI: 10.36290/neu.2021.025

Opportunistic infections of the central nervous system in human immunodeficiency virus-(HIV-) infected individuals

doc. MUDr. Hanuš Rozsypal, CSc.
Klinika infekčních a tropických nemocí, 1. lékařská fakulta, Univerzita Karlova a Fakultní Nemocnice Bulovka, Praha

Impairment of the nervous system may occur practically anytime during of human immunodeficiency virus (HIV)-infection. Diseases may be either primary - caused directly by HIV - or secondary - infections caused by various microorganisms or neoplasms. With worsening of cellular immunodeficiency, conditions for opportunistic infections arise. The opportunistic infections include particularly three typical diagnoses: toxoplasmic encephalitis, cryptococcus meningitis, and progressive multifocal leukoencephalopathy (PML). Antiretroviral therapy (ART) has changed significantly incidence of CNS complications, opportunistic infections occur less frequently, primary cerebral lymphoma is rare nowadays. Nevertheless, after starting of an efficient regimen, at least minimal signs of neurocognitive disorder can be found in many patients.

Keywords: HIV (human immunodeficiency virus) infection, HIV-associated neurocognitive disorders (HAND), opportunistic infection, brain toxoplasmosis, progressive multifocal leukoencephalopathy (PML), Cryptococcus meningitis.

Received: April 13, 2021; Revised: April 13, 2021; Accepted: April 13, 2021; Prepublished online: April 13, 2021; Published: September 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rozsypal H. Opportunistic infections of the central nervous system in human immunodeficiency virus-(HIV-) infected individuals. Neurol. praxi. 2021;22(4):278-282. doi: 10.36290/neu.2021.025.
Download citation

LMm_References

  1. Antinori A, Ammassari A, Giancola ML, Cingolani A, Grisseti S, Murri R, Alba L, Ciancio B, Soldoni F, Larussa D, Ippolito G, De Luca A. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol 2001; 7: 323-328. Go to original source... Go to PubMed...
  2. Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, Domingo P, Márquez M, Rodriguez-Arrondo FJ, Laguna F, Rubio R, Rodrigo HL, Mallolas J, de Miguel D. GESIDA 11/99 Study Group. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36: 1047-1052. Go to original source... Go to PubMed...
  3. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, Roque C, Rajicic N, McAuliffe V, Morlat P, Jayaweera DT, Vilde JL, Luft BJ. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002; 34: 1243-1250. Go to original source... Go to PubMed...
  4. De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J, Di Giambenedetto S, Cingolani A, Taoufik Y, Miralles P, Marra ChM, Antinori A, Gesida 9/99, IRINA, ACTG 363 Study Groups. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008; 22: 1759-1767. Go to original source... Go to PubMed...
  5. Eng PM, Turnbull BR, Cook SF, Davidson JE, Kurth T, Seeger JD. Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology 2006; 67(5): 884-6. Go to original source... Go to PubMed...
  6. Falco V, Olmo M, del Saz SV, Guelar A, Santos JR, Gutiérrez M, Colomer D, Deig E, Mateo G, Montero M, Pedrol E, Podzamczer D, Domingo P, Llibre JM. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J AIDS 2008; 49: 26-31. Go to original source... Go to PubMed...
  7. Fessler RD, Sobel J, Guyot L, Crane L, Vazquez J, Szuba MJ, Diaz FG. Management of elevated intracranial pressure in patients with Cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17(2): 137-42. Go to original source... Go to PubMed...
  8. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W.Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30(1): 47-54. Go to original source... Go to PubMed...
  9. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, McArthur J, Hollander H, Yainnoutsos C, Major E, Millar L, Timpone J. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with HIV infection. N Engl J Med 1998; 338: 1345-1351. Go to original source... Go to PubMed...
  10. Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22: 268-275. Go to original source... Go to PubMed...
  11. Marzocchetti A, Tompkins T, Clifford DB. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009; 73: 1551-1558. Go to original source... Go to PubMed...
  12. Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22(Suppl 2): S119-S123. Go to original source... Go to PubMed...
  13. Royal W 3rd, Dupont B, McGuire D, Chang L, Goodkin K, Ernst T, Post MJ, Fish D, Pailloux G, Poncelet H, Concha M, Apuzzo L, Singer E. Topotecan in the treatment of acquired immunodeficiency syndromerelated progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9: 411-419. Go to original source... Go to PubMed...
  14. Rozsypal H, Jilich D, Hubáček P, Holub M. Úskalí diagnostiky progresivní multifokální leukoencefalopatie u pacientů infikovaných lidským virem imunodeficience - kazuistiky. Česk Slov Neurol N 2013; 76/109(4): 501-507.
  15. Suzuki Y. Immunopathogenesis of cerebral toxoplasmosis. J Infect Dis 2002; 186(Suppl. 2): S234-S240. Go to original source... Go to PubMed...
  16. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 2009; 72(17): 1458-1464. Go to original source... Go to PubMed...
  17. Walot I, Miller BL, Chang L, Mehringer CM. Neuroimaging findings in patients with AIDS. Clin Infect Dis 1996; 22: 906-19. Go to original source... Go to PubMed...
  18. Wei H, Hai W, Wanqing L. Clinical study on liposomal amphotericin B (AmBisome) in deep fungal infections in China. Mycoses 2003; 46(1-2): 24-28. Go to original source... Go to PubMed...
  19. White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy - revisited. J Infect Dis 2011; 203: 578-586. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.